MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/pdm.0b013e3181359e1f

Медицинская библиотека · Diagnostic molecular pathology : the American journal of surgical pathology, part B · 2008

Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer.

Capizzi Elisa, Gabusi Elena, Grigioni Antonia D'Errico, De Iaco Pierandrea, Rosati Marta, Zamagni Claudio, Fiorentino Michelangelo

Контролируемое клиническое исследованиеСтатьяПеревод в очереди

Аннотация

OBJECTIVES

A nonrandomized trial was planned to investigate the role of free plasma DNA (FPDNA) in patients with epithelial ovarian cancer before and after chemotherapy. Twenty-two patients with advanced stage ovarian cancer not suitable for debulking were treated with a neoadjuvant platinum/taxanes chemotherapy. Patients with clinical complete or partial response underwent radical hystero-oophorectomy, omentectomy, and lymphadenectomy and were followed up every 3 to 6 months.

METHODS

Blood samples were obtained from each patient before chemotherapy, before each cycle, before and after surgery. FPDNA was quantified by real-time quantitative polymerase chain reaction using the Quantifiler Human Quantification Kit and expressed in ng/mL. Fifty female healthy blood donor volunteers were used as controls.

RESULTS

Median FPDNA quantities discriminated between patients before chemotherapy (29.6+/-22.7 ng/mL) and controls (6.4+/-4.0 ng/mL) using a 14.5 ng/mL cutoff with 77% sensitivity and 96% specificity (P<0.001). Mean FPDNA concentrations significantly decreased after chemotherapy (17.9+/-14.5 ng/mL, P=0.001). A peak of FPDNA levels (66.2+/-45.2 ng/mL) was observed in association with surgery (P<0.001). Median follow-up and median progression-free survival time were 13.4+/-5.1 and 11.7+/-5.6 months, respectively. Eight patients with FPDNA values above the cutoff after chemotherapy showed disease progression or died, whereas 7 patients with FPDNA below the cutoff were free from disease. Patients with FPDNA levels above and below the cutoff showed significantly separated progression-free survival curves (P=0.007, log-rank test).

CONCLUSIONS

FPDNA quantification significantly discriminates between cancer patients and controls and correlates with response to chemotherapy. Although performed in a limited series, we demonstrated a correlation between FPDNA values and clinical behavior of ovarian cancer patients.

Для цитирования: Capizzi Elisa, Gabusi Elena, Grigioni Antonia D'Errico, De Iaco Pierandrea, Rosati Marta, Zamagni Claudio, Fiorentino Michelangelo. Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer.. Diagnostic molecular pathology : the American journal of surgical pathology, part B. 2008. DOI: 10.1097/pdm.0b013e3181359e1f.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.